the clinical and pathological data of 45 patients with ovarian mucinous tumors were analyzed retrospectively, and their clinicopathological features were summarized in order to analyze the clinicopathological features of ovarian mucinous tumors. There were 30 cases of benign ovarian mucinous tumors (66.67%), 4 cases of borderline tumors (8.89%), 11 cases of malignant tumors (24.44%), 9 cases of primary malignant tumors (20%) and 2 cases of secondary malignant tumors (4.44%). The morphological spectrum of ovarian mucinous tumors is widely expressed, and the close combination of pathological examination and clinical examination is of great significance for diagnosis and treatment.

Zhou Zhiling. Clinicopathological analysis of ovarian mucinous tumor. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 7: 38-43. https://doi.org/10.25236/AJMHS.2023.040707.

[1] Su Y J, Zhou L, Jing L J, et al. Clinicopathological characteristics of 46 cases with ovarian metastatic tumors of digestive tract origin [J]. Chinese Journal of Experimental Diagnostics, 2013, 17(3):511-515. 

[2] Han Zhijiang, Shu Yanyan, Lai Xifeng, et al. CT differential diagnosis of ovarian serous cystadenoma and mucinous cystadenoma [J]. Chinese Journal of Medical Sciences, 2010, 12(12):1677-1680. 

[3] Tang ZR, Bu Yan-yan. A clinicopathological analysis of 19 cases of mucinous borderline tumor of ovary [J]. Med Info,2013,(28):207. 

[4] An Yunting, Zheng Zwen. Clinical analysis of 36 cases of supratdermal neoplasms of egg nest crossing [J]. Modern Oncology Medicine,2009,17(8):1538-1540.

[5] Mei Li, Yue Jun, Xie LAN, et al. Clinicopathological analysis of 54 cases of borderline ovarian tumors [J]. Western Medicine,2012,24(5):858-860,863

[6] Horrée N, vail Diest P J, van der Groep P, et a1.Progressive de—railment of cell cycle regulators in endometrial carcinogenesis[J].J Clin Pathol, 2008, 61(1): 36-42

[7] Zhou Y, Shen J, Xia L, Wang Y, Estrogen mediated expressionof nucleophosmin l in human endometrial carcinoma clinical stages through estrogen receptor—q signaling[J].Cancer Cell Int, 2014,14(1):540.

[8] Borriello A, Caldarelli I, Bencivenga D , et al .p57(Kip2) and cancer : time for a critical appraisal [J]. Mol Cancer Res,2011,9(10):1269-84..

[9] Zhou Zhengping, Xiao Qingbang, Luo Zuqiang. Relationship between the expression of p57Kip2, CyclinE and clinicopathological features in endometrioid adenocarcinoma [J]. Cancer Prevention and Treatment Research, 2013,40 (9) : 860-3.

[10] Borges K S, Arboleda V A, Vilain E . Mutations in the PCNA - binding site of CDKNIC inhibit cell proliferation by impairing the entry into S phase [J]. Cell Div,2015,10:2.

[11] Xu X Y, Wang W Q . Zhang L . et al . Clinical implications of p573 expression in breast cancer [ J ]. Asian Pac J Cancer Prev 2013,2(1):26-31. (in Chinese)

[12] Luo Zuqiang, Zhou Zhengping, Gesang Zhima, Xiao Qingbang. Expression and significance of p57kip2, ER and PR in endometrial carcinoma and different endometrial lesions [J]. Journal of Clinical & Experimental Pathology, 2013,29(9):982-5. 

[13] Huang Wenqian, Kong Jingyi, ZHANG Shi-Qian. Problems related to the diagnosis and treatment of peritoneal pseudomyxoma. Chinese Journal of Applied Gynecology and Obstetrics, 2015,31 (11) : 1008-1012 

[14] Zhou Y, Shen J, Xia L, Wang Y . Estrogen mediated expression of nucleophosmin I in human endometrial carcinoma clinical stages through estrogen receptor -c signaling [J]. Cancer Cell Int,2014,14(1):540.

[15] Matsuoka S, Edwards M C, Bai C, et al.p57h, a structurally distinct member of the p21CIPI CDK inhibitor family , is a candi-date tumor suppressor gene [J]. Genes Dev,1995,9(6):650-62. 

[16] Zhang Lili, Wang Jianliu. Estrogen activates calcium ion flow through non-genetic effects to regulate the signaling kinase pathway in endometrial cancer cells [J]. Journal of Peking University (Med), 2015,47 (3) : 489-93.

[17] Sun Weigang, The pathology and histological classification of endometrial carcinoma [J]. Journal of Practical Obstetrics and Gynecology, 2008,24(5):259-62. 

[18] Vang R, Khunamornpong S, Kobel M, et al.WHO Classification of Tumours of the Female Genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer, 2020.48 -53.

[19] Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors of intestinal type)and carcinomas, including an evaluation of 11 cases withpseudomyxoma peritonei .Am J Surg Pathol, 2000, 24 (11) : 1447 -1464.

[20] Prat J, D'angelo E, Espinosa I.Ovarian carcinomas: at least fivedifferent diseases with distinct histological features and moleculargenetics.Hum Pathol, 2018, 80: 11 -27.

[21] Muyldermans K, Moerman P, Amant F, et al.Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases.Eur J Cancer, 2013, 49(7) : 1600 -1608.

[22] Lee KR, Young RH.The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases.Am J Surg Pathol, 2003, 27( 3) : 281 -292.

[23] Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.Gynecol Oncol, 2009, 113( 3) : 331 -334.

[24] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019.CA Cancer J Clin, 2019, 69( 1) : 7 -34.

[25] Kajiyama H, Suzuki S, Utsumi F, et al.Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma.Int J Clin Oncol, 2019, 24( 8) : 950 -956.